Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 17/20 | 0.51 |
| ▸ | RORA | P35398 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21072988 | 0.86 | RORC (0.52) | RORCPKM | |
| SCHEMBL19165200 | 0.86 | MOGAT2 (0.47) | RORCRORAPKMMOGAT2 | |
| SCHEMBL21073503 | 0.84 | PKM (0.62) | RORCPKM | |
| SCHEMBL21073145 | 0.80 | PKM (0.55) | RORCPKM | |
| SCHEMBL21072963 | 0.80 | BRD4 (0.57) | RORC | |
| SCHEMBL21072961 | 0.79 | RORC (0.50) | RORCRORAPKM | |
| SCHEMBL21073502 | 0.78 | RORC (0.51) | RORCRORAMOGAT2 | |
| SCHEMBL21073158 | 0.77 | RORC (0.63) | RORCRORA | |
| SCHEMBL21073134 | 0.77 | RORC (0.52) | RORCRORA | |
| SCHEMBL21072953 | 0.75 | NR1H3 (0.70) | RORCRORA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210161837-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210161837-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-03 | — | — | US | disclosed |
| US-20190192454-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190192454-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192454-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | RORA, RORB, RORC | RORC 3/4885RORA 1/4885PKM 3347/4885 |
| US-20210161837-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | RORA, RORB, RORC | RORC 3/4885RORA 1/4885PKM 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.